Proprotein convertase subtilisn/kexin type 9 inhibitors and small interfering RNA therapy for cardiovascular risk reduction: A systematic review and meta-analysis.
Tasnim F ImranAli A KhanPhinnara HasAlexis JacobsonStephanie BoginMahnoor KhalidAsim KhanSamuel KimSebhat ErqouGaurav ChoudharyKaren AspryWen-Chih WuPublished in: PloS one (2023)
PCSK9 inhibitors (Evolocumab, Alirocumab) and siRNA therapy (Inclisiran) significantly reduced LDL-c by >40% in high-risk individuals. Additionally, both Alirocumab and Evolocumab reduced the risk of MACE, and Alirocumab reduced cardiovascular and all-cause mortality.